360 related articles for article (PubMed ID: 19302475)
1. The novel NMDA receptor antagonist, 2-hydroxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzoic acid, is a gating modifier in cultured mouse cortical neurons.
Noh J; Lee ES; Chung JM
J Neurochem; 2009 Jun; 109(5):1261-71. PubMed ID: 19302475
[TBL] [Abstract][Full Text] [Related]
2. Functional in vitro characterization of CR 3394: a novel voltage dependent N-methyl-D-aspartate (NMDA) receptor antagonist.
Losi G; Lanza M; Makovec F; Artusi R; Caselli G; Puia G
Neuropharmacology; 2006 Mar; 50(3):277-85. PubMed ID: 16236334
[TBL] [Abstract][Full Text] [Related]
3. Equilibrium constants for (R)-[(S)-1-(4-bromo-phenyl)-ethylamino]-(2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)-methyl]-phosphonic acid (NVP-AAM077) acting at recombinant NR1/NR2A and NR1/NR2B N-methyl-D-aspartate receptors: Implications for studies of synaptic transmission.
Frizelle PA; Chen PE; Wyllie DJ
Mol Pharmacol; 2006 Sep; 70(3):1022-32. PubMed ID: 16778008
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of NMDA-gated ion channels by bis(7)-tacrine: whole-cell and single-channel studies.
Liu YW; Luo JL; Ren H; Peoples RW; Ai YX; Liu LJ; Pang YP; Li ZW; Han YF; Li CY
Neuropharmacology; 2008 Jun; 54(7):1086-94. PubMed ID: 18407299
[TBL] [Abstract][Full Text] [Related]
5. Excitotoxicity in vitro by NR2A- and NR2B-containing NMDA receptors.
von Engelhardt J; Coserea I; Pawlak V; Fuchs EC; Köhr G; Seeburg PH; Monyer H
Neuropharmacology; 2007 Jul; 53(1):10-7. PubMed ID: 17570444
[TBL] [Abstract][Full Text] [Related]
6. Underlying mechanism for NMDA receptor antagonism by the anti-inflammatory drug, sulfasalazine, in mouse cortical neurons.
Noh JH; Gwag BJ; Chung JM
Neuropharmacology; 2006 Jan; 50(1):1-15. PubMed ID: 16169564
[TBL] [Abstract][Full Text] [Related]
7. Knockdown of the aryl hydrocarbon receptor attenuates excitotoxicity and enhances NMDA-induced BDNF expression in cortical neurons.
Lin CH; Chen CC; Chou CM; Wang CY; Hung CC; Chen JY; Chang HW; Chen YC; Yeh GC; Lee YH
J Neurochem; 2009 Nov; 111(3):777-89. PubMed ID: 19712055
[TBL] [Abstract][Full Text] [Related]
8. Agonist concentration dependency of blocking kinetics but not equilibrium block of N-methyl-D-aspartate receptors by memantine.
Gilling KE; Jatzke C; Parsons CG
Neuropharmacology; 2007 Sep; 53(3):415-20. PubMed ID: 17632186
[TBL] [Abstract][Full Text] [Related]
9. Role of the NR2A/2B subunits of the N-methyl-D-aspartate receptor in glutamate-induced glutamic acid decarboxylase alteration in cortical GABAergic neurons in vitro.
Monnerie H; Hsu FC; Coulter DA; Le Roux PD
Neuroscience; 2010 Dec; 171(4):1075-90. PubMed ID: 20923697
[TBL] [Abstract][Full Text] [Related]
10. Effect of Conantokin G on NMDA receptor-mediated spontaneous EPSCs in cultured cortical neurons.
Alex AB; Baucum AJ; Wilcox KS
J Neurophysiol; 2006 Sep; 96(3):1084-92. PubMed ID: 16760339
[TBL] [Abstract][Full Text] [Related]
11. Marked prevention of ischemic brain injury by Neu2000, an NMDA antagonist and antioxidant derived from aspirin and sulfasalazine.
Gwag BJ; Lee YA; Ko SY; Lee MJ; Im DS; Yun BS; Lim HR; Park SM; Byun HY; Son SJ; Kwon HJ; Lee JY; Cho JY; Won SJ; Kim KW; Ahn YM; Moon HS; Lee HU; Yoon SH; Noh JH; Chung JM; Cho SI
J Cereb Blood Flow Metab; 2007 Jun; 27(6):1142-51. PubMed ID: 17106444
[TBL] [Abstract][Full Text] [Related]
12. State-dependent NMDA receptor antagonism by Ro 8-4304, a novel NR2B selective, non-competitive, voltage-independent antagonist.
Kew JN; Trube G; Kemp JA
Br J Pharmacol; 1998 Feb; 123(3):463-72. PubMed ID: 9504387
[TBL] [Abstract][Full Text] [Related]
13. Lipid emulsions reduce NMDA-evoked currents.
Weigt H; Georgieff M; Beyer C; Georgieff EM; Kuhse J; Föhr KJ
Neuropharmacology; 2004 Sep; 47(3):373-80. PubMed ID: 15275826
[TBL] [Abstract][Full Text] [Related]
14. Factors that enhance ethanol inhibition of N-methyl-D-aspartate receptors in cerebellar granule cells.
Popp RL; Lickteig RL; Lovinger DM
J Pharmacol Exp Ther; 1999 Jun; 289(3):1564-74. PubMed ID: 10336554
[TBL] [Abstract][Full Text] [Related]
15. Identification and characterization of novel NMDA receptor antagonists selective for NR2A- over NR2B-containing receptors.
Bettini E; Sava A; Griffante C; Carignani C; Buson A; Capelli AM; Negri M; Andreetta F; Senar-Sancho SA; Guiral L; Cardullo F
J Pharmacol Exp Ther; 2010 Dec; 335(3):636-44. PubMed ID: 20810618
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of NMDA-induced current by the putative NR2B selective antagonist ifenprodil.
Zhang XX; Bunney BS; Shi WX
Synapse; 2000 Jul; 37(1):56-63. PubMed ID: 10842351
[TBL] [Abstract][Full Text] [Related]
17. Structural modifications to an N-methyl-D-aspartate receptor antagonist result in large differences in trapping block.
Mealing GA; Lanthorn TH; Small DL; Murray RJ; Mattes KC; Comas TM; Morley P
J Pharmacol Exp Ther; 2001 Jun; 297(3):906-14. PubMed ID: 11356910
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological characterization, localization, and regulation of ionotropic glutamate receptors in skate horizontal cells.
Kreitzer MA; Birnbaum AD; Qian H; Malchow RP
Vis Neurosci; 2009; 26(4):375-87. PubMed ID: 19678977
[TBL] [Abstract][Full Text] [Related]
19. Long-lasting NMDA receptor-mediated EPSCs in mouse striatal medium spiny neurons.
Logan SM; Partridge JG; Matta JA; Buonanno A; Vicini S
J Neurophysiol; 2007 Nov; 98(5):2693-704. PubMed ID: 17804581
[TBL] [Abstract][Full Text] [Related]
20. Long-term potentiation in the nucleus accumbens requires both NR2A- and NR2B-containing N-methyl-D-aspartate receptors.
Schotanus SM; Chergui K
Eur J Neurosci; 2008 Apr; 27(8):1957-64. PubMed ID: 18412616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
